Literature DB >> 22508824

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.

Su-Jung Kim1, Dong-Wan Kim, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo, Yung-Jue Bang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22508824     DOI： 10.1200/JCO.2011.39.9766

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer.

Authors:  Min Yu; Shuang Zhang; Meijuan Huang; You Lu
Journal:  Mol Clin Oncol       Date:  2014-04-16

Review 2.  Targeted therapies and immunotherapy in non-small-cell lung cancer.

Authors:  D Cortinovis; M Abbate; P Bidoli; S Capici; S Canova
Journal:  Ecancermedicalscience       Date:  2016-06-23

3.  Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer.

Authors:  Giacomina Megaro; Evelina Miele; Gian Paolo Spinelli; Iside Alessi; Giada Del Baldo; Raffaele Cozza; Ida Russo; Maria Debora De Pasquale; Maria Giuseppina Cefalo; Paolo Tomà; Andrea Carai; Valentina Di Ruscio; Maria Antonietta De Ioris; Angela Mastronuzzi
Journal:  Cancer Rep (Hoboken)       Date:  2022-01-28

4.  Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma.

Authors:  Spyridon Gennatas; Susana J Stanway; Robert Thomas; Toon Min; Riyaz Shah; Mary E R O'Brien; Sanjay Popat
Journal:  BMC Cancer       Date:  2013-04-26       Impact factor: 4.430

5.  Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy.

Authors:  Qiushi Wang; Yong He; Xin Yang; Yubo Wang; Hualiang Xiao
Journal:  BMC Pulm Med       Date:  2014-05-15       Impact factor: 3.317
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.